NCT04954339View on ClinicalTrials.gov

DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 29, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Aatezolizumab plus Bevacizumab

Two cycles of naeoadjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) prior to surgical resection and four cycles of adjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) after the surgery will be administered.

Trial Locations (1)

138736

Asan Medical Center, Seoul

All Listed Sponsors
lead

Tae Won Kim

OTHER